RICHMOND, Va.--(BUSINESS WIRE)--Insmed Incorporated (NASDAQ:INSM) announced today that it has sued Tercica, Inc. for allegedly false and misleading statements Tercica has made in advertising and promoting Increlex™, Tercica’s Severe Primary IGFD treatment. In a counterclaim filed in the United States District Court for the Eastern District of Virginia, Insmed charges that Tercica has made numerous unlawful, false and misleading statements Increlex and/or IPLEX™, the only once daily treatment for children with short stature associated with severe primary IGF-I deficiency (Primary IGFD).
